Yahoo Web Search

Search results

1. • 

     EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer

     Pharmaceutical Technology via Yahoo Finance· 1 hour ago

     This study assessed Tagrisso in combination with pemetrexed and platinum-based chemotherapy in 557...

2. • Tumors shrink for 62% of patients in Merck study

     Becker’s Hospital Review· 6 days ago

     In a phase 2/3 trial investigating the efficacy of Keytruda with two chemotherapies, tumors shrank among 3 in 5 patients with pleural mesothelioma, Merck said May 29. It often progresses rapidly ...

3. • 

     BMS secures another EC approval for Opdivo combination

     Pharmaceutical Technology via Yahoo Finance· 6 days ago

     Previously, there were no marketed therapies that improved overall survival in patients with...

4. • 

     Secondhand Smoke Increases Cisplatin Resistance in HNC

     Medscape· 5 days ago

     Dr Maurie Markman discusses results from a study suggesting that secondhand smoke exposure may...

5. • Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion

     Zacks· 5 days ago

     Free Report) announced that the European Commission (EC) has approved its blockbuster immuno-oncology drug, Opdivo (nivolumab), in combination with a chemotherapy combination ...

6. • 

     ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours

     Clinical Trials Arena via Yahoo Finance· 1 day ago

     The therapy was evaluated as a monotherapy and in combination with AbbVie’s investigative programmed...

7. • 

     EMA Panel Nods to Seven New Cancer Drugs

     Medscape· 4 days ago

     The drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.

8. • Engineered DNA 'warhead' targets a common cancer mutation

     Medical Xpress· 5 days ago

     Tumor protein P53 (TP53) plays an important role in suppressing the growth of tumors. Mutations in the gene for TP53 can have a disastrous effect, hampering the body's ability to fight tumors ...

9. • AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative...

     The Longview News-Journal· 7 days ago

     New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ...